Indevus Announces FDA Acceptance of IND for NEBIDO(R); Company to Commence Pharmacokinetic Trial in Men with (FinanzNachrichten)
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's Investigational New Drug ("IND") application for NEBIDO, its long-acting injectable testosterone preparation for the treatment of male hypogonadism.